3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Osteosarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Liposarcoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
11
Gemcitabine
10
Doxorubicin
10
Cyclophosphamide
9
Specimen Handling
8
Nivolumab
8
Ibandronic Acid
8
pazopanib
7
Radiosurgery
6
Magnetic Resonance Spectroscopy
6
Imatinib Mesylate
6
Biopsy
6
Bevacizumab
6
Irinotecan
5
regorafenib
4
Zoledronic Acid
4
Ipilimumab
4
Ifosfamide
4
Fluorouracil
4
Docetaxel
4
Cetuximab
4
sargramostim
3
conatumumab
3
cemiplimab
3
Sunitinib
3
Radiation
3
Paclitaxel
3
Leucovorin
3
Cryosurgery
3
Cisplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Clinical Trials, Phase II as Topic
×
Sarcoma
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled